aggressive variant b16f0 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
96
Structured Review
ATCC
aggressive variant b16f0
Aggressive Variant B16f0, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1366 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggressive+variant+b16f0/B16-F0/pm40875545-52-8-11
Average 96 stars, based on 1366 article reviews
Aggressive Variant B16f0, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1366 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggressive+variant+b16f0/B16-F0/pm40875545-52-8-11
Average 96 stars, based on 1366 article reviews
aggressive variant b16f0 - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Variant Assay:Article Title: Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment. Article Snippet: The main limitations of cancer treatment with high doses of recombinant interleukin 2 (IL-2) are high toxicity and the undesired expansion of regulatory T cells.. The generation of IL-2 mutated variants (muteins) with changes in the affinity for different chains of the IL-2 receptor (IL-2R) allows selective stimulation of effector cells while overcoming its toxicity.. As increasing the IL-2 affinity for the IL-2R beta chain leads to better antitumor effect, we generated a group of these muteins using phage display technology, in a previous work. Cell Culture:Article Title: Enhanced affinity for the IL-2 receptor β subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment. Article Snippet: The main limitations of cancer treatment with high doses of recombinant interleukin 2 (IL-2) are high toxicity and the undesired expansion of regulatory T cells.. The generation of IL-2 mutated variants (muteins) with changes in the affinity for different chains of the IL-2 receptor (IL-2R) allows selective stimulation of effector cells while overcoming its toxicity.. As increasing the IL-2 affinity for the IL-2R beta chain leads to better antitumor effect, we generated a group of these muteins using phage display technology, in a previous work. |